Dresden

• A study to test how well an oral medication called rilzabrutinib works and how safe it is for adults with immune thrombocytopenia (ITP) who … Recruiting
  2025-522070-36-00 5 2025-12-15 immune thrombocytopenia (ITP)
• SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting
  2025-520794-39-00 5 2025-12-10 Arterial Hypertension
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or … Recruiting
  2025-521034-28-00 4 2025-12-05 Moderate to Severe Rheumatoid Arthritis (RA)
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 4 2025-11-25 Mantle Cell Lymphoma (MCL)
• An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518006-40-00 5 2025-11-13 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
• A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers … Recruiting
  2025-521658-40-00 1 2025-10-27 Atopic dermatitis
• A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s … Recruiting
  2024-519623-23-00 5 2025-10-20 Venous leg ulcer
• A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting
  2024-519795-11-00 4 2025-10-06 Atopic Dermatitis
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting
  2024-516790-78-00 4 2025-09-04 stage IV NSCLC (non-small-cell lung cancer)
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD) Recruiting
  2023-505946-24-00 5 2025-05-15 Primary Immunodeficiency Diseases
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 5 2025-05-02 melanoma, cutaneous malignant
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer

Showing 97–120 of 943 trials